Search clinical trials for: Recommended number of sessions

Total 431531 results

Sanofi

Recruiting

Implementation and Evaluation of a Rare Disease Algorithm to Identify Persons at Risk of Gaucher Disease Using Data From Electronic Health Records (EHRs) in the United States (Project Searchlight)

Gaucher Disease

United States
Genentech, Inc.
Chugai Pharmaceutical Co.

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Gastric Cancer | Metastatic Solid Tumor | Non-small Cell Lung Cancer | Pancreatic Ductal Adenocarcinoma

Korea, Republic of, Spain, Japan, New Zealand, Australia, United States, Italy, Brazil
Hoffmann-La Roche

Recruiting

A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

Breast Cancer

Korea, Republic of, United States, Israel, Denmark, Argentina, Brazil, Germany, Mexico, Peru, Poland, Spain, Taiwan, South Africa, Netherlands, Czechia, Italy, Australia, Hungary
Sanofi Pasteur, a Sanofi Company

Recruiting

Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (MEQ00064)

Healthy Volunteers | Meningococcal Immunisation

South Africa, India
Sanofi

Recruiting

Cold Agglutinin Disease Real World Evidence Registry (CADENCE)

Cold Agglutinin Disease (CAD) | Cold Agglutinin Syndrome (CAS)

United States, Austria, France, Italy, Germany, Japan, Spain, United Kingdom
Sanofi

Recruiting

Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (ATLANTIS)

Dermatitis Atopic

Italy, United Kingdom, Argentina, France, Chile, Czechia, Germany, Japan, Spain, China, Netherlands, Brazil, Canada, Denmark, Korea, Republic of, South Africa, Taiwan, Poland, India, Mexico
Sanofi
Regeneron Pharmaceuticals

Recruiting

A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))

Colitis Ulcerative

Argentina, Korea, Republic of, Mexico, United States, Canada, Chile, Japan, Puerto Rico, South Africa, Taiwan, Turkey
Sanofi

Recruiting

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

Plasma Cell Myeloma

Czechia, Australia, Chile, France, Spain, United States, Brazil, China, Greece, Japan, Korea, Republic of, Sweden, Taiwan, Finland, Italy, Russian Federation
Sanofi

Recruiting

A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia (ATLAS-NEO)

Hemophilia

Greece, Korea, Republic of, France, Taiwan, Italy, Spain, United States, Canada, China, Germany, India, Japan, Mexico, South Africa, Turkey, Poland, Saudi Arabia
Sanofi

Recruiting

Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis (RESOLUTE)

Colitis Ulcerative

Argentina, Chile, United States, China, Czechia, France, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Spain, United Kingdom
Sanofi

Recruiting

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

Solid Tumor

United States, Israel, Netherlands, Spain
Kadmon, a Sanofi Company

Recruiting

Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy

Chronic Graft Versus Host Disease

United States
Sanofi
Regeneron Pharmaceuticals

Recruiting

A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids)

Chronic Spontaneous Urticaria

United States, Canada, Japan
Sanofi

Recruiting

Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials (RIVER-AD)

Dermatitis Atopic

Canada, United States, Australia, Bulgaria, Czechia, Germany, Hungary, Japan, Poland, Spain, Taiwan, United Kingdom
Sanofi

Recruiting

Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (MAYARI)

Thrombotic Thrombocytopenic Purpura

Italy, Belgium, France, Greece, United States, Austria, Canada, Czechia, Germany, Japan, Netherlands, Spain, United Kingdom
Sanofi

Recruiting

Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors

Neoplasm

United States, Canada, China, Korea, Republic of, Singapore
Sanofi

Recruiting

Data Analysis of Adult and Pediatric Participants With Acid Sphingomyelinase Deficiency (ASMD) on Early Access to Olipudase Alfa in France (OPERA)

Acid Sphingomyelinase Deficiency (ASMD)

France
Amunix, a Sanofi Company
Merck Sharp & Dohme LLC

Recruiting

To Access the Safety and Effects of Intravenous Administration of AMX-818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

Locally Advanced or Metastatic HER2-Expressing Cancers

Australia, Spain, France, Portugal
Sanofi
Regeneron Pharmaceuticals

Recruiting

Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD (AERIFY-3)

Chronic Obstructive Pulmonary Disease

United States, Netherlands, Belgium, Denmark, Germany, United Kingdom, Brazil
Merck Sharp & Dohme LLC

Recruiting

Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006/KEYVIBE-006)

Carcinoma, Non-Small-Cell Lung

United States, Australia, Brazil, Chile, China, Costa Rica, Dominican Republic, Germany, Greece, Guatemala, Israel, Italy, Japan, Korea, Republic of, Malaysia, Mexico, Spain, Turkey, Ukraine, Portugal, Romania, South Africa, Philipp...
Sanofi

Recruiting

A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease (CARAT)

Fabry Disease

Italy, United States, Austria, China, Czechia, Denmark, France, Germany, Greece, Japan, Korea, Republic of, Netherlands, Norway, Spain, Taiwan, Turkey, United Kingdom, Canada, Poland
Sanofi

Recruiting

Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)

Pruritus

Poland, China, Spain, Italy, Japan, United States, Canada, France, Germany, Hungary, Korea, Republic of, Argentina
Sanofi

Recruiting

Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)

Osteogenesis Imperfecta

United States, Australia, Canada, France
Sanofi

Recruiting

Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3 (LEAP2MONO)

Gaucher's Disease Type III

United States, Germany, Hungary, France, China, Japan, Canada, Argentina, Italy, Turkey
Sanofi

Recruiting

A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease (PERIDOT)

Fabry Disease

China, Finland, Germany, Norway, United Kingdom, United States, Denmark, Austria, Greece, Romania, Argentina, Brazil, Canada, Japan, Mexico, Poland, Italy, France, Turkey, Australia, Switzerland
Sanofi

Recruiting

BIVV020 (SAR445088) n Prevention and Treatment of Antibody-mediated Rejection (AMR)

Transplant Rejection

Germany, Italy, Spain, United States, Canada, France, Sweden
Sanofi
Regeneron Pharmaceuticals

Recruiting

Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma (ATLAS)

Asthma

Belgium, Brazil, Romania, United Kingdom, Slovakia, Hungary, Mexico, South Africa, Turkey, Greece, United States, Bulgaria, Canada, India, Ireland, Korea, Republic of, Oman, Puerto Rico, Taiwan, United Arab Emirates, Saudi Arabia
Affiliated Hospital of Nantong University

Recruiting

Effect of HMP on Diabetic Microangiopaemia in T2DM

Diabetes Mellitus, Type 2 | Diabetic Angiopathies

China
Sanofi

Recruiting

First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Myelodysplastic Syndromes | Acute Lymphocytic Leukaemia | Acute Myeloid Leukaemia Refractory | Blastic Plasmacytoid Dendritic Cell Neoplasia

Netherlands, France, United States, Australia, China
Sanofi

Recruiting

Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus (APATURA)

Systemic Lupus Erythematosus

Chile, Brazil, Greece, Italy, Spain, United States, Argentina, Hungary, Mauritius, Mexico, Russian Federation, Turkey, Ukraine, Puerto Rico, Switzerland
Merck Sharp & Dohme LLC
Eisai Inc.

Recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)

Metastatic Esophageal Squamous Cell Carcinoma

Argentina, Chile, United States, Canada, China, Costa Rica, Denmark, France, Guatemala, Hong Kong, Hungary, Italy, Japan, Korea, Republic of, Russian Federation, Spain, Taiwan, Turkey, United Kingdom, Romania, Ukraine, Singapore, Ma... and more
Sanofi

Recruiting

Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa (Baby-COMET)

Glycogen Storage Disease Type II

Belgium, United States, China, Germany, Italy, Netherlands, Spain, Taiwan, United Kingdom
Sanofi

Recruiting

A Prospective Study to Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD)

Glycogen Storage Disease Type II

Belgium, United States, Italy, Spain, Taiwan, United Kingdom, Netherlands, France, Germany
Sanofi

Recruiting

A Non-Interventional National Study in Pediatric Patients With Unexplained Enlarged Spleen (OPPUS)

Acid SphingoMyelinase Deficiency | Gaucher Disease, Splenomegaly

France
Sanofi Pasteur, a Sanofi Company

Recruiting

Observational, Passive Surveillance Program to Collect Information on Women and Their Offspring Exposed to MenQuadfi® During Pregnancy, in United States (US)

Meningococcal Infection

United States
Sanofi
Regeneron Pharmaceuticals

Recruiting

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-2)

Chronic Obstructive Pulmonary Disease

Korea, Republic of, Turkey, United States, Chile, Czechia, Israel, Russian Federation, Argentina, Brazil, Bulgaria, Canada, Denmark, Estonia, France, Georgia, Germany, Hungary, India, Japan, Latvia, Lithuania, Mexico, Netherlands, Norway and more
Sanofi

Recruiting

Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors

Cancer | Neoplasm

United States, Israel
Sanofi
Regeneron Pharmaceuticals

Recruiting

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-1)

Chronic Obstructive Pulmonary Disease

Bulgaria, China, United States, Argentina, Chile, Czechia, Georgia, Greece, Hungary, India, Israel, Italy, Mexico, Poland, Romania, Russian Federation, Slovakia, Taiwan, Ukraine, United Kingdom, Mauritius
Sanofi

Recruiting

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Plasma Cell Myeloma Refractory

France, Australia, Greece, Italy, Norway, United States, Portugal, Puerto Rico, Germany
Principia Biopharma, a Sanofi Company

Recruiting

Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) (LUNA 3)

Immune Thrombocytopenia

United States, China, Argentina, Australia, Brazil, Canada, France, Hungary, Israel, Korea, Republic of, Mexico, Russian Federation, Singapore, Spain, Thailand, United Kingdom, Austria, Chile, Germany, Italy, Japan, Netherlands, Norway and more
Sanofi

Recruiting

Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS) (PERSEUS)

Primary Progressive Multiple Sclerosis

Spain, Italy, Turkey, India, Israel, Bulgaria, Mexico, Greece, Portugal, United States, Argentina, Australia, Austria, Belarus, Belgium, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Estonia, France, Georgia, Germany, Hungary, Japan and more
Sanofi

Recruiting

A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) (IONA-MM)

Plasma Cell Myeloma

Germany, United States, Argentina, China, France, Hong Kong, Italy, Japan, Puerto Rico, Spain, Switzerland, United Arab Emirates, United Kingdom, Austria, Belgium, Netherlands, Taiwan
Merck Sharp & Dohme LLC
Eisai Inc.

Recruiting

Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

Squamous Cell Carcinoma of Head and Neck

United States, Australia, Canada, Denmark, France, Israel, Korea, Republic of, Norway, Portugal, Romania, Spain, Taiwan, United Kingdom, Colombia, Brazil
Instituto de Investigación Marqués de Valdecilla
Hospital de laredo; Hospital Sierrallana

Recruiting

Transdiagnostic Group Cognitive Behavioral Therapy (PsicAP-A) for Adolescents With Emotional Disorders (PsicAP-A)

Emotional Disorder

Spain
Synthorx, Inc, a Sanofi company

Recruiting

A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101) (HAMMER)

Metastasis

United States, Australia, Singapore, Spain, Argentina, Chile
Sanofi

Recruiting

Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD)

Dermatitis Atopic

Norway, Spain, Argentina, Israel, Greece, United States, Australia, Brazil, Canada, China, Colombia, Denmark, France, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Portugal, Russian Federation
Genzyme, a Sanofi Company

Recruiting

Pompe Pregnancy Sub-Registry

Pompe Disease (Late-onset) | Glycogen Storage Disease Type II (GSD-II) | Glycogenesis 2 Acid Maltase Deficiency

Croatia, United States, Italy, Belgium, Czechia
Genzyme, a Sanofi Company

Recruiting

International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

Gaucher Disease | Cerebroside Lipidosis Syndrome | Glucocerebrosidase Deficiency Disease | Glucosylceramide Beta-Glucosidase Deficiency Disease

Hungary, Croatia, United States, Australia, Belgium, Brazil, Bulgaria, Canada, Denmark, Germany, Greece, Hong Kong, India, Indonesia, Italy, Jordan, Korea, Republic of, Kuwait, Lebanon, Malaysia, Pakistan, Philippines, Poland, Saudi Arabia and more
Genzyme, a Sanofi Company

Recruiting

Pompe Disease Registry Protocol

Glycogen Storage Disease Type II | Pompe Disease

Hungary, Croatia, Serbia, United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Denmark, France, Germany, Greece, Hong Kong, India, Indonesia, Israel, Italy, Japan, Jordan, Korea, Republic of, Kuwait and more
Sanofi

Completed

Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS) (phaethuSA)

Sjogren's Syndrome | Sjögren's Syndrome

Belgium, Taiwan, Korea, Republic of, United States, Argentina, Canada, Chile, France, Germany, Hungary, Mexico, Spain

Search clinical trials for: Recommended number of sessions

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations